• KGS/USD = 0.01146 0%
  • KZT/USD = 0.00193 -0%
  • TJS/USD = 0.10153 0%
  • UZS/USD = 0.00008 -0%
  • TMT/USD = 0.28571 0%
  • KGS/USD = 0.01146 0%
  • KZT/USD = 0.00193 -0%
  • TJS/USD = 0.10153 0%
  • UZS/USD = 0.00008 -0%
  • TMT/USD = 0.28571 0%
  • KGS/USD = 0.01146 0%
  • KZT/USD = 0.00193 -0%
  • TJS/USD = 0.10153 0%
  • UZS/USD = 0.00008 -0%
  • TMT/USD = 0.28571 0%
  • KGS/USD = 0.01146 0%
  • KZT/USD = 0.00193 -0%
  • TJS/USD = 0.10153 0%
  • UZS/USD = 0.00008 -0%
  • TMT/USD = 0.28571 0%
  • KGS/USD = 0.01146 0%
  • KZT/USD = 0.00193 -0%
  • TJS/USD = 0.10153 0%
  • UZS/USD = 0.00008 -0%
  • TMT/USD = 0.28571 0%
  • KGS/USD = 0.01146 0%
  • KZT/USD = 0.00193 -0%
  • TJS/USD = 0.10153 0%
  • UZS/USD = 0.00008 -0%
  • TMT/USD = 0.28571 0%
  • KGS/USD = 0.01146 0%
  • KZT/USD = 0.00193 -0%
  • TJS/USD = 0.10153 0%
  • UZS/USD = 0.00008 -0%
  • TMT/USD = 0.28571 0%
  • KGS/USD = 0.01146 0%
  • KZT/USD = 0.00193 -0%
  • TJS/USD = 0.10153 0%
  • UZS/USD = 0.00008 -0%
  • TMT/USD = 0.28571 0%

Viewing results 1 - 6 of 26

Tajikistan’s Pharmaceutical Sector Remains Heavily Dependent on Imports

Despite possessing vast reserves of medicinal plants, Tajikistan's pharmaceutical industry remains heavily reliant on imports. Experts are increasingly questioning why the sector has been reduced to a basic "buy-and-sell" model and what is hindering the use of the country’s natural resources. Abundant Resources, Limited Output Tajikistan is home to more than 3,500 species of medicinal plants, including licorice, mint, valerian, chamomile, motherwort, and even rare saffron. However, this natural wealth has not translated into pharmaceutical independence. In the past two years alone, Tajikistan has imported roughly $84 million worth of medicines. Currently, 67 pharmaceutical companies are registered in the country, producing around 600 types of drugs. Still, imported pharmaceuticals dominate the market. According to industry observers, the sector has evolved into a retail-focused trade, rather than a hub for research-based production. During the Soviet era, pharmaceuticals in Tajikistan were closely integrated with scientific institutions. Research institutes flourished, pharmacies compounded custom medications, and both training and quality control were rigorous. Following the collapse of the USSR, this infrastructure disintegrated. The responsible state committee was dissolved, and a previously regulated system was replaced by an unstructured market. Today, training programs are often accelerated, pharmacists’ qualifications are inconsistent, and the emphasis has shifted from treatment to sales. A Pharmacy That Heals Amid this decline, one notable exception is found in the city of Isfara, where a phytotherapy department has been established at the local hospital. Spearheaded by pharmacist Abubakr Faiziev, the department operates out of a restored facility where locally gathered herbs are used to produce traditional infusions and decoctions. Faiziev personally collects about half of the ingredients. “It is important to me that the pharmacy heals, not just sells,” he said. According to Faiziev, approximately 80% of patients return for follow-up treatment, often bypassing conventional doctors due to the perceived effectiveness of herbal therapies, a sentiment echoed even among members of the local elite. A Science in Decline Faiziev laments the erosion of scientific ambition in the country. "People now ask for business plans and guaranteed profits instead of pursuing knowledge. But science doesn’t work that way," he said. Research, he noted, has become sporadic and often relies on outdated data, with little interest from private companies in investing in innovation. Young professionals, too, are increasingly opting for commercial routes. “They prefer to open pharmacies for fast income rather than engage in research,” he explained. “There are many pharmacists now. But we must transform quantity into quality. Without passion for the profession, one cannot become a skilled expert.” The State’s Role and Untapped Potential President Emomali Rahmon has repeatedly stressed the need to develop the domestic pharmaceutical industry and better utilize Tajikistan’s natural resources. Ongoing reforms include updates to medical university curricula, the opening of laboratories, and the training of technologists and quality control specialists. Yet, experts argue that without a comprehensive, systematic strategy and active engagement from the private sector, these measures are insufficient. Faiziev advocates for the creation of a pharmaceutical technology park and the development of both the domestic...

Polpharma Group to Boost Pharmaceutical Production and Exports in Kazakhstan

Kazakhstan’s national investment promotion agency, Kazakh Invest, has signed a Memorandum of Cooperation with Polpharma Group, a leading pharmaceutical manufacturer in Central and Eastern Europe, the Caucasus, and Central Asia. The agreement marks the launch of a €55 million investment project in Kazakhstan by SANTO, a member of the Polpharma Group. The memorandum was signed by Azamat Kozhanov, Deputy Chairman of Kazakh Invest’s Management Board, and Markus Sieger, CEO of Polpharma Group. Over the next decade, the project is expected to create approximately 300 jobs and significantly increase domestic pharmaceutical production, particularly for medications targeting socially significant diseases such as cancer, diabetes, and cardiovascular conditions. The initiative includes the introduction of new manufacturing lines, expanded R&D investment, and the development of training programs in line with international standards. This strategic partnership supports Kazakhstan’s national goal of increasing local pharmaceutical production to 50% of domestic demand. It also aims to position the country as a regional hub for pharmaceutical manufacturing and exports. “We are aware that President Kassym-Jomart Tokayev has set a clear objective to boost local pharmaceutical output to 50%, and we fully support this vision,” said Markus Sieger. “The COVID-19 pandemic revealed the vital importance of resilient, domestic supply chains. Our goal is not only to strengthen production in Kazakhstan but to transform the country into an export hub for large regional markets.” SANTO currently holds six Good Manufacturing Practice (GMP) certificates and has successfully passed inspections by the European Union. The company is now anticipating certification under EU GMP standards, which would provide access to EU markets for both the company and Kazakhstan’s broader pharmaceutical sector. Polpharma Group continues to expand its footprint in Central Asia. In 2024, 12% of the company’s global sales came from the region, a figure that is expected to grow further. The development of a pharmaceutical hub in Kazakhstan will enhance the country’s position in both domestic and international markets. These new investments, along with the expected GMP EU certification, are set to strengthen Kazakhstan’s global pharmaceutical competitiveness, reduce reliance on imports, and improve national pharmaceutical security.

Kyrgyzstan Gears Toward Self-Sufficiency in Medication

Kyrgyzstan has taken a significant step toward reducing its dependence on imported pharmaceuticals with the launch of domestic medicine production at the Aidan Pharma pharmaceutical plant. The facility has begun manufacturing its first batch of essential medications, including: Paracetamol (suspensions and tablets); Ibuprofen (suspensions); Acetylsalicylic acid (tablets); and Acyclovir (tablets). The plant has the capacity to produce up to 10,000 packages of each of these medicines per day, offering an important boost to the country’s pharmaceutical industry. In late 2023, Aidan Pharma began producing medical ethyl alcohol, which is now supplied to state hospitals and pharmacies. During a visit to the plant on January 10, Health Minister Alymkadyr Beishenaliev announced plans to expand the plant’s product range to 100 items by the end of this year. He also revealed that the company intends to begin exporting its products in the future. “The plant's products meet quality standards and have a low production cost, making them more affordable compared to imported medicines,” Beishenaliev noted. The Kyrgyz government has prioritized reducing the country’s reliance on imported medications. In December 2024, the Cabinet of Ministers approved an investment agreement for a Kyrgyz-Chinese pharmaceutical project led by Standard Pharm Group. This initiative will focus on packaging pharmaceuticals and constructing a new pharmaceutical plant in Kyrgyzstan. The project, which will be implemented in two stages over five years, is expected to attract over $41 million in investment. According to Minister of Economy and Commerce Bakyt Sydykov, the plant will manufacture a range of medicines, including: Nutritional infusions; Antibacterial, anti-inflammatory, and antipyretic medications; Analgesics; Hypoglycemic treatments; and Gastrointestinal drugs. Most of these medicines are included in Kyrgyzstan’s List of Vital Medicines, a critical inventory of essential pharmaceuticals that are currently not produced domestically. The development of Kyrgyzstan’s pharmaceutical industry marks a critical shift toward self-sufficiency in healthcare. By expanding domestic production, the government aims to make essential medications more accessible and affordable for its population while fostering economic growth through investment and exports.

Swiss Company Roche to Produce Anti-Cancer Drugs in Almaty

On October 24, the Swiss pharmaceutical giant F. Hoffmann-La Roche Ltd., in partnership with Nobel Almaty Pharmaceutical Factory JSC, launched the production of innovative drugs in Almaty. The project followed an agreement between Roche, Kazakhstan’s SK-Pharmacy LLP, Nobel, and the Kazakh Research Institute of Oncology and Radiology, with the support of National Company Kazakh Invest. Under the agreement, Roche committed to establishing local production of three biotechnological drugs for the treatment of HER2-positive breast cancer, an aggressive form of the disease that affects up to 20% of breast cancer patients in Kazakhstan. At the opening ceremony, Kazakhstan's Minister of Health, Akmaral Alnazarova, said: "The localization [of production] of oncological drugs by a global leader like Roche is a huge step forward for our country. This project will provide patients access to advanced treatments and significantly contribute to developing Kazakhstan's healthcare infrastructure.” The transfer of Roche's advanced technologies and production capabilities to local partners will reduce healthcare system costs in Kazakhstan and significantly expand patient access to essential medicines. Around 5,000 new cases of breast cancer are registered in the country annually, with approximately 1,200 resulting in death. This project is expected to increase the number of patients receiving therapy to 1,335 by 2026. The project is part of Kazakhstan’s plan to increase the share of domestically produced medicines and medical devices to 50%.

Uzbekistan and Kazakhstan Sign $5 Billion in Agreements at Business Forum

On August 7, a joint business forum was held in Astana with more than 300 representatives from business circles of Uzbekistan and Kazakhstan in attendance. At the forum, joint projects involving automotive engineering, electrical engineering, pharmaceuticals, the chemical and logistics industries were discussed, and a set of agreements with a total value of $5 billion were adopted, according to the Agency for the Development of the Pharmaceutical Network. A memorandum of understanding was signed between Kazakhstan’s JV KAZ AMT and Uzbekistan’s Estess Atraumatic Sterile Surgical Threads LLC, Kazakhstan’s Dolche LLC and Uzbekistan’s Medproject Technology LLC. The President of the Republic of Uzbekistan, Shavkat Mirziyoyev, arrived in Astana on August 7 at the invitation of the President of Kazakhstan. Within the framework of the visit, Mirziyoyev will participate in the consultative meeting of the leaders of the Central Asian countries and the dialogue in the format Central Asia + Japan. President Mirziyoyev signed the decision to establish a free economic zone of the Central Asia International Industrial Cooperation Center on August 6. The zone will be organized in the Syr Darya region. Industrial cooperation will be expanded by involving enterprises in the production process in the center's territory and establishing the production of import-substituting products. Only products manufactured in Uzbekistan and Kazakhstan are sold in the center's territory under the control of a production certificate. According to the decision, Kazakhstani and foreign citizens can enter the center's territory without a visa through a special checkpoint with an identity document, and stay in the territory for 15 days.

Chinese Company Opens Genetic Laboratory in Astana

Kazakh Invest has reported that the opening ceremony of the Astana Genetic Center laboratory of the Chinese company BGI Group took place in Kazakhstan’s capital, Astana, on July 19. BGI Group, a world leader in genome research of living organisms, has over a hundred joint laboratories, medical centers, and production facilities in more than 30 countries. The opening ceremony was attended by Yin Ye, CEO of BGI Group; Kunsulu Zakariya, Advisor to the President of Kazakhstan on Science and Innovation; Akmaral Alnazarova, Kazakhstan’s Minister of Health; and Saule Sabyr, First Secretary of the Investment Committee of the Kazakh Ministry of Foreign Affairs. BGI Group opened the laboratory jointly with a local partner, scientific and production company BIOGEN Technopark LLP. The laboratory will conduct various molecular genetic tests related to reproductive health and diagnosis of hereditary and oncological diseases. The Astana Genetic Center is the only full-cycle laboratory in Kazakhstan capable of conducting all stages of genetic research without taking biomaterial abroad.